Open Public Hearing FDA Advisory Committee on AMX0035 March 30, 2022 Good afternoon. My name is Andrea Pauls Backman, CEO of the Les Turner ALS Foundation. My only disclosure is that the Les Turner ALS Foundation receives less than 2% …
Nearly $1 Million in ALS Grants Awarded in 2022
The Les Turner ALS Foundation is excited to announce nearly $1 million to be funded in 2022 for new research grants and clinic and endowment support to the Les Turner ALS Center at Northwestern Medicine! These discoveries would not have …
Comments on Amylyx Pharmaceuticals’ New Drug Application for AMX0035
RE: Docket No. FDA-2018-N-0410 Dear FDA Advisory Committee: Founded in 1977, the Les Turner ALS Foundation is the oldest independent ALS group in the country. For 45 years, it has been our mission to provide the most comprehensive care and …
Faces of ALS: Joshua Cohen and Justin Klee – ALS Innovators and Advocates at Amylyx Pharmaceuticals, Inc.
At this year’s Hope Through Caring Gala on May 21, we are proud to present the Harvey and Bonny Gaffen Advancements in ALS Award to two innovators and longtime advocates of ALS – Joshua Cohen and Justin Klee, co-founders of …
LiveLikeLou’s Outdoor Clean-up and Scholarships
With spring in the air, there’s no better time than now to tackle those outdoor chores with a little help from your (volunteer) friends. Thanks to our partners at the LiveLikeLou Foundation, they are offering volunteer assistance and an opportunity …
Response to NINDS Request for Information on ALS Strategic Plan
February 11, 2022 Dear NINDS, As we set our sights on shaping the strategic future of ALS research, we thank you for the opportunity to identify key research and priorities at NIH and beyond. We also recognize …
Les Turner ALS Symposium Celebrates Advances in Research and Patient Care
BY MELISSA ROHMAN ON NOV 4, 2021 Northwestern scientists and clinicians demonstrated their continued commitment to advancing knowledge and therapies for amyotrophic lateral sclerosis (ALS) during the 11th annual Les Turner Symposium on ALS. The virtual, daylong symposium featured scientific presentations highlighting the molecular …
Biogen Briefing Notes – Scientific Advisory Council (SAC)
The following note is being passed along from the Board of Directors of the International Alliance of ALS/MND Associations… The Board of Directors of the International Alliance of ALS/MND Associations is pleased to provide information for Member Associations in the …
AMX0035 May Slow ALS Progression and Extend Life
On September 15, Amylyx Pharmaceuticals announced its intention to submit a New Drug Application to the FDA for AMX0035 for the treatment of ALS. If the New Drug Application is successful, AMX0035 would be only the third drug approved by …
Les Turner ALS Foundation’s Andrea Pauls Backman Advocates for “Bold, Urgent Methods” to Improve Access to Potential ALS Treatments
In response to a recent congressional hearing focused on the slow pace of drug approvals for neurological diseases, Les Turner ALS Foundation’s CEO Andrea Pauls Backman spoke with Suz Redfearn, a reporter for FDA News. Andrea was quoted extensively in …
